Latest in Misidentified Newly
Sort by
2 items
-
-
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.MarketWatch - 3d